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ABSTRACT
Background: Prescription opioid abuse remains an ongoing public
health crisis, especially in orthopaedic surgery. The purpose of the
present study is to analyze opioid-prescribing patterns and investigate
risk factors for prolonged opioid use after common outpatient
orthopaedic surgical procedures.
Methods: After institutional review board approval, a review of 1,384
patients undergoing common elective outpatient orthopaedic
procedures from January 2018 to June 2019 was conducted. Data on
controlled substance prescriptions were obtained from the
prescription drug monitoring program website. Statistical analysis was
done to identify predictors for a second opioid prescription and
prolonged opioid use (.6 months).
Results: Over 10% (150/1,384) of patients were still using opioids
beyond 6 months. Of the opioid exposed patients, 60.4% (174/288)
filled at least 1 additional opioid prescription postoperatively, and
29.2% (84/288) filled prescriptions beyond 6 months, compared with
26.4% (289/1,096) and 6.0% (66/1,096) of opioid-naive patients,
respectively. Following multivariate analysis, significant predictors for
filling a second opioid prescription included preoperative opioid use,
current smoker status, benzodiazepine use, psychiatric disorder, and
advanced age.
Conclusion: This study revealed risk factors for prolonged opioid use
after orthopaedic surgery. Surgeons should be mindful of these risk
factors and counsel patients regarding postoperative pain
management.

DOI: 10.5435/JAAOSGlobal-D-21-00226

C

onsiderable efforts have been made to curtail opioid abuse
by minimizing postoperative pain and opioid use with the introduction of preoperative counseling, multimodal pain strategies intraoperatively and postoperatively, and statewide online prescription drug
monitoring programs (PDMPs). However, opioid abuse continues to remain a
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After institutional review board approval, a retrospective
review of 1,699 patients undergoing common outpatient
orthopaedic procedures was conducted from January
2019 to June 2019 at a single institution. Inclusion criteria included patients at least 18 years old who underwent a surgical procedure from January 2018 to June
2019 at our institution, and patients were identified via a
database query. Elective outpatient orthopaedic proce-

dures selected for analysis included distal biceps repair
(Current Procedural Terminology [CPT] 24342), rotator
cuff repair (CPT 29827), anterior cruciate ligament
reconstruction (CPT 29888), Achilles tendon repair
(CPT 27650), hallux valgus correction (CPT 28295,
28296), and thumb basal joint arthroplasty (CPT
25447). Patients were excluded if they underwent more
than one surgical procedure during the study period, or
if they did not fill an initial postoperative opioid prescription. A cohort of 1,699 patients met the initial
inclusion criteria, and of those, 1,383 patients could be
identified in the PDMP system and filled their initial
postoperative opioid prescription. Data obtained from
institutional databases included demographic information, alcohol use, smoking status, and medical history. A
history of psychiatric disorder was defined as having
anxiety and/or depression.
The Pennsylvania PDMP website was used to identify
controlled substance prescriptions filled by study subjects.
States included in the Pennsylvania PDMP search include
Pennsylvania, Arkansas, Connecticut, Delaware, Florida,
Louisiana, Maine, Maryland, Massachusetts, Military
Health System, Minnesota, New York, North Carolina,
Ohio, Oklahoma, Rhode Island, South Carolina, Texas,
Virginia, and West Virginia. The PDMP system has been
previously validated and was proven to be reliable and
accurate in controlled substance reporting.19 From
6 months preoperatively to 9 months postoperatively, all
controlled substance prescriptions filled by each patient
were recorded. This included opioids, benzodiazepines,
stimulants, and nonbenzodiazepine sedative hypnotics.
Additional information gathered from the PDMP system
included prescription amount, prescription fill date, and
the type of insurance that was used to purchase the
controlled substance prescriptions. Patients who filled
one controlled substance prescription during the 6-month
preoperative period were considered opioid exposed to
that controlled substance. Patients who did not fill any
controlled substance prescriptions during the preoperative period were considered to be opioid naive to controlled substances. Postoperative dependent outcomes
investigated included (1) filling an additional opioid
prescription postoperatively and (2) prolonged opioid use
greater than 6 months postoperatively. Patient characteristics and controlled substance use were analyzed to
determine risk factors for these outcomes.
Continuous data are presented as mean (SD), and categorical data are presented as counts (%). Continuous and
categorical data were initially analyzed with independent
Student t-test and chi-square testing, respectively, to
observe significant associations. The investigated variables
April 2022, Vol 6, No 4
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costly health burden.1,2 Opioid abuse and its health and
societal ramifications cost the US healthcare system in
excess of $78 billion annually.3-5 In 2018, 46,802
people died as a result of opioid overdose, with nearly
one-third being from opioid prescriptions.6 Orthopaedic
surgeons have been identified as high prescribers for
opioids,7 and therefore, effective postoperative pain
management protocols could help curtail the opioid
epidemic.
The use of opioids after orthopaedic surgery has been
explored in the literature. Studies have demonstrated that
chronic opioid abuse leads to worse functional outcomes,
delayed return to work, increased revision rates, and
increased risk for postoperative infections.8-10 Preoperative opioid counseling and postoperative evidencebased opioid prescribing have shown to decrease opioid consumption while maintaining high satisfaction.11-13 In addition, multimodal pain management and
interscalene blocks have proven effective means of
postoperative pain control after upper extremity surgery.14,15 However, long-term opioid use after elective
surgery is of particular concern, with Brummett et al16
identifying an approximate 6% rate of prolonged opioid
use after major and minor general surgeries. Prolonged
use is potentially representative of opioid abuse and
dependency. Recently, studies in the arthroplasty literature have used PDMP systems to identify predictors of
second postoperative opioid prescription rates and
prolonged use beyond 6 months.17,18
It is relevant for orthopaedic surgeons to investigate
factors that may place certain patients at risk for developing long-term opioid abuse after orthopaedic surgery.
A patient developing chronic opioid abuse is not only
detrimental to postoperative outcomes but also to a patient’s overall health and to the healthcare system as a
whole. The purpose of the present study is to investigate
risk factors for prolonged opioid use after common
elective outpatient orthopaedic surgical procedures
using a state PDMP.
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Table 1.

Descriptive Statistics of Patients Who Filled an Additional Opioid Prescription and Who Had Prolonged Opioid Use .6 months Postoperatively

Variable

Total,
N = 1,383

No Second Opioid
Rx, N = 921

Filled a Second Opioid
Rx, N = 462

P

No Prolonged Opioid
Use, N = 1,234

Prolonged .6-mo
Opioid Use, N = 149

P

Age (SD)

50.2 (16.9)

47.7 (17.2)

55.3 (15.1)

,0.001

49.2 (17.1)

58.3 (12.8)

,0.001

Sex

0.009

0.507

Female

596 (43.1%)

374 (40.6%)

223 (48.2%)

528 (42.8%)

69 (46.0%)

Male

787 (56.9%)

547 (59.4%)

240 (51.8%)

706 (57.2%)

81 (54.0%)

28.1 (5.5)

27.6 (5.16)

29.0 (5.90)

,0.001

27.8 (5.35)

30.2 (5.93)

,0.001

287 (20.8%)

114 (12.4%)

174 (37.6%)

,0.001

204 (16.5%)

84 (56.0%)

,0.001

67 (4.8%)

40 (4.34%)

27 (5.83%)

0.278

60 (4.86%)

7 (4.67%)

1

153 (11.1%)

61 (6.62%)

92 (19.9%)

,0.001

119 (9.64%)

34 (22.7%)

,0.001

Preop sedative
hypnotic exposed

65 (4.7%)

32 (3.47%)

33 (7.13%)

0.004

55 (4.46%)

10 (6.67%)

0.316

Use of .1 controlled
substances

109 (7.9%)

30 (3.26%)

79 (17.1%)

,0.001

74 (6.00%)

35 (23.3%)

,0.001

Alcohol use

886 (68.9%)

589 (69.1%)

297 (68.4%)

0.871

791 (69.1%)

95 (66.4%)

0.573

Current smoker

124 (11.4%)

62 (8.60%)

62 (17.0%)

,0.001

99 (10.3%)

25 (20.7%)

0.001

27 (2.1%)

17 (2.01%)

10 (2.31%)

0.88

24 (2.11%)

3 (2.10%)

1

BMI (SD)
Preop opioid exposed
Preop stimulant
exposed
Preop benzodiazepine
exposed

Recreational drug use

94 (11.1%)

112 (25.7%)

,0.001

158 (13.8%)

48 (33.6%)

,0.001

7 (0.6%)

4 (0.48%)

3 (0.70%)

0.695

5 (0.44%)

2 (1.42%)

0.178

Diabetes

88 (6.4%)

44 (4.78%)

44 (9.50%)

0.001

65 (5.27%)

23 (15.3%)

,0.001

Osteoporosis

67 (5.3%)

26 (3.08%)

41 (9.51%)

,0.001

43 (3.80%)

24 (16.8%)

,0.001

Sleep apnea

136 (10.6%)

72 (8.51%)

64 (14.8%)

0.001

105 (9.24%)

31 (21.8%)

,0.001

12 (0.9%)

5 (0.59%)

7 (1.61%)

0.121

8 (0.71%)

4 (2.80%)

0.036

Psychiatric disorder

Stroke
Insurance type
Nongovernment
Government

0.004

0.02

1,234
(89.2%)

838 (91.0%)

397 (85.7%)

1,110 (90.0%)

125 (83.3%)

150 (10.8%)

83 (9.01%)

66 (14.3%)

124 (10.0%)

25 (16.7%)

Data are represented as number (percentage) or mean (SD).
BMI = body mass index, Preop = preoperative, Rx = prescription
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Variable

Achilles,
N = 128

Filled another Rx

20.3% (26)

Prolonged .6-mo use
Preop opioid usage

ACLR, N = 433

BJA, N = 149

DBR, N = 62

HVC, N = 69

22.6% (14)

29.0% (20)

21.7% (94)

45.0% (67)

3.9% (5)

3.2% (14)

16.8% (25)

14.5% (9)

16.4% (21)

11.1% (48)

26.2% (39)

17.7% (11)

Opioid Exposed Versus Naive

RCR, N = 542

Total, N = 1,383

P

Opioid,
Naive,
N = 1,096

Opioid
Exposed,
N = 287
60.4% (174)

,0.001
,0.001

44.5% (241)

33.4% (462)

,0.001

26.4% (289)

11.6% (8)

16.2% (88)

10.8% (149)

,0.001

6.0% (66)

29.2% (84)

14.5% (10)

29.2% (158)

20.8% (287)

,0.001

—

100% (287)

P

—

Avg no. Rxs

1.2 (0.4)

1.4 (1.3)

3.3 (3.8)

2.2 (2.2)

2.4 (2.0)

3.0 (3.3)

2.6 (3.0)

—

2.6 (3.0)

—

Total MME
received

149.1
(135.3)

378.3 (1,398.9)

2,459.0
(4,769.9)

1,128.4
(2,582.0)

1,116.5
(2,165.2)

3,244.9
(13,556.5)

2,276.9
(10,303.9)

—

2,276.9
(10,303.9)

—

Avg MME/
Rx

127.2 (99.1)

159.6 (212.8)

628.4 (1,392.7)

259.6 (335.7)

266.4 (293.0)

418.6 (796.9)

371.0 (802.6)

—

371.0 (802.6)

—

295.5
(136.0)

329.2 (209.1)

164.7 (159.0)

183.1 (90.9)

211.4 (69.4)

309.6 (223.2)

290.6 (221.8)

283.7 (170.0)

305.4 (297.6)

0.237

Mean MME of the initial
Rx
Postop opioid usage

,0.001

20.3% (26)

21.7% (94)

45.0% (67)

22.6% (14)

29.0% (20)

44.5% (241)

33.4% (462)

Avg no. Rxs

1.6 (1.5)

1.6 (1.1)

3.4 (4.9)

2.2 (1.6)

2.3 (2.8)

3.1 (4.1)

2.7 (3.7)

1.6 (1.1)

4.5 (5.4)

,0.001

Total MME
received

295.4
(352.5)

330.2 (610.1)

2,284.2
(6,403.0)

633.2 (867.8)

842.1 (2,512.7)

2,792.1
(11,736.4)

1,927.2 (8,895.2)

309.7 (283.1)

4,629.1
(14,149.2)

,0.001

Avg MME/
Rx

169.9 (73.7)

178.9 (129.2)

282.3 (414.9)

221.7 (217.0)

194.7 (215.7)

365.2 (577.7)

292.5 (460.6)

186.0 (106.3)

470.5 (706.2)

,0.001

ACLR = anterior cruciate ligament reconstruction, Avg = average; BJA = basal joint arthroplasty, DBR = distal biceps repair, HVC = hallux valgus correction, MME = morphine milligram equivalents, Preop = preoperative,
Postop = postoperative; RCR = rotator cuff repair, Rx = prescription
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Multivariate Regression With an Additional
Opioid Prescription as the Dependent Outcome
Odds Ratio (95% CI)

P

Preop opioid use

3.37 (2.44–4.66)

,0.001

Preop benzodiazepine
use

1.76 (1.11–2.80)

0.015

Age

1.02 (1.01–1.03)

,0.001

Smoker

1.95 (1.29–2.96)

0.002

Psychiatric disorder

1.81 (1.25–2.62)

0.002

Variable

CI = confidence interval, Preop = preoperative

were selected based on clinical relevance and analyzed for
association with the primary outcomes. A stepwise
multivariate regression for each primary outcome was
then built using the significant variables. Variables with
P . 0.25 were eliminated. Finally, the area under the
curve (AUC) was calculated to determine the accuracy
of the stepwise regression models for each outcome

variable. Statistical significance was set at P , 0.05. All
statistical analyses were done using R Studio (Version
3.6.3).

Results
Overall, 1,383 patients were identified in the PDMP system and filled their initial postoperative opioid prescription. Patient mean age was 50.2 years (SD 16.9), with 787
men (56.9%) and 596 women (43.1%) (Table 1). With
respect to preoperative controlled substance use, 20.8%
used opioids, 11.1% used benzodiazepines, 4.8% used
stimulants, 4.7% used nonbenzodiazepine sedative
hypnotic medications, and 7.9% used more than one type
of controlled substance. Additional demographic data are
summarized in Table 1. The mean opioid prescription
amount in total morphine milligram equivalents (MMEs)
prescribed on the day of surgery was 290.6 MMEs (SD
221.8), which is equivalent to 39 tablets of 5 mg

Figure 1
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AUC curve for the regression model with an additional opioid prescription as the dependent outcome. The AUC value is 0.726.
AUC = area under the curve

© American Academy of Orthopaedic Surgeons

5

Research Article

Table 3.
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scription; however, this difference was not statistically
significant (294.9 MME versus 284.9 MME; P = 0.449)
Following stepwise multivariate analysis, the following
independent risk factors (in order of decreasing significance)
were associated with filling an additional opioid prescription: preoperative opioid use (odds ratio [OR] 3.37; P ,
0.001), current smoker status (OR 1.95; P = 0.002), history
of psychiatric disorder (OR 1.81; P = 0.002), preoperative
benzodiazepine use (OR 1.76; P = 0.015), and older age
(OR 1.02; P # 0.001) (Table 3). The AUC value, which
represents the accuracy of a regression model, for the
regression predicting an additional opioid prescription was
0.726 (Figure 1).

Table 4.

Multivariate Regression With Prolonged
.6-Month Opioid Use as the Dependent Outcome
P

Preop opioid use

5.91 (3.89–9.06)

,0.001

BMI

1.03 (0.99–1.07)

0.059

Age

1.03 (1.01–1.04)

0.002

Government insurance

0.60 (0.31–1.14)

0.128

Smoker

2.01 (1.16–3.41)

0.011

Osteoporosis

2.14 (1.06–4.22)

0.030

Sleep apnea

2.17 (1.24–3.75)

0.006

BMI = body mass index, CI = confidence interval, Preop =
preoperative

Prolonged Opioid Use .6 Months

oxycodone. The type and number of procedures done are
included in Table 2.

Preoperatively Opioid Exposed Versus Naive
Within 6 months preoperatively, over 20% (287/1,383)
of patients in this study used opioids, representing the
opioid-exposed patients. These patients received an
average of 2.6 prescriptions for a total of 2,276.9
MMEs (average of 371.0 MME/Rx) within 6 months
before their surgery. Opioid-exposed patients were
prescribed a slightly larger, but not statistically significant, opioid prescription on the day of their surgery for
postoperative pain than did opioid-naive patients
(305.4 MME versus 283.7 MME; P = 0.237). In
addition, 60.6% (174/287) of opioid-exposed patients
filled at least 1 additional opioid prescription postoperatively compared with 26.4% (289/1,096) of
opioid-naive patients (P , 0.001). In addition, of the
opioid-exposed patients, 29.3% (84/287) continued to
fill opioid prescriptions beyond 6 months postoperatively compared with only 6.0% (66/1,096) of opioidnaive patients (P , 0.001). Overall, during the 12-month
postoperative period, opioid-exposed patients filled
significantly more opioid prescriptions (4.5 versus 1.6;
P , 0.001), received significantly higher total amount in
MMEs (4,629.1 versus 309.7; P , 0.001), and received
larger prescriptions by average MME/Rx (470.5 versus
186.0; P , 0.001) than did opioid-naive patients
(Table 2).

Second Opioid Prescription

6
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A second opioid prescription was filled by 33.4%
(462/1,383) of patients. Patients who filled at least one
additional opioid prescription postoperatively were
prescribed a slightly larger initial postoperative opioid prescription than the patients who did not fill a second pre-

Prolonged opioid use .6 months postoperatively was
observed in 10.8% (149/1,383) of patients. Following
stepwise multivariate regression analysis, the following
independent variables (in order of decreasing significance) were associated with prolonged .6-month opioid use: preoperative opioid use (OR 5.91; P , 0.001),
history of sleep apnea (OR 2.17; P = 0.006), history of
osteoporosis (OR 2.14; P = 0.030), current smoker
status (OR 2.01; P = 0.011), and advanced age (OR
1.03; P = 0.002) (Table 4). The AUC value for this
regression model predicting prolonged .6-month opioid use was 0.706 (Figure 2).

Procedure Type
The type and number of procedures done are included in
Table 2. Mean total MMEs of the initial postoperative
opioid prescription for specific procedure types ranged
from 164.7 MMEs (SD 159.0) (equivalent of 21 tablets
of 5 mg oxycodone) for basal joint arthroplasty (BJA) to
329.2 MMEs (SD 209.1) (equivalent of 44 tablets of
5 mg oxycodone) for anterior cruciate ligament reconstruction (Table 2). For all procedures, there were more
patients who filled additional opioid prescriptions postoperatively than there were patients who used opioids
preoperatively. Significantly more rotator cuff repair
(RCR) patients (29.2%) and BJA patients (26.2%) used
opioids preoperatively compared with the other procedures (P , 0.001). Postoperatively, significantly more
BJA patients (45.0%) and RCR patients (44.5%) filled a
second opioid prescription compared with the other
procedures (P , 0.001). Prolonged .6-month opioid use
postoperatively was observed in significantly more BJA
patients (16.8%), RCR patients (16.2%), and distal
biceps repair patients (14.5%) than the other procedures
(P , 0.001). Postoperatively, BJA and RCR patients
received more opioid prescriptions and a higher total
April 2022, Vol 6, No 4
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Odds Ratio (95% CI)

Variable
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Figure 2

AUC curve for the regression model with prolonged .6-month opioid use as the dependent outcome. The AUC value for this curve is
0.706. AUC = area under the curve
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Journal of the AAOS Global Research & Reviews ®

-----

In an effort to combat the national opioid epidemic,
healthcare providers and researchers continue to investigate different strategies to manage postsurgical
pain.1,2,14,20 This study identifies independent risk factors for filling an additional opioid prescription and
prolonged opioid use after common elective outpatient
orthopaedic surgical procedures. As cited in previous
studies, preoperative opioid exposure was a significant
risk factor for prolonged opioid use postoperatively. In
addition, a history of smoking and advanced age were
risk factors for both filling an additional opioid prescription and prolonged opioid use. To our knowledge,
this study represents the largest sample of PDMP data
currently published in the literature; our hope is that our

findings can be used to aid in identifying patients at risk
for prolonged opioid use and prevent possible addiction.
Our study identified a long-term use of opioids postoperatively, as defined as .6 months, to be 10.8%,
with a rate of 6.0% in the opioid-naive cohort. This is
consistent with other studies within the literature. Jiang
et al7 found that chronic opioid use (.3 months)
prevalence to be on average 9.2% across different surgical subspecialties in opioid-exposed and -naive patients. In a large 2017 insurance claims database study,
Brummett et al16 found that opioid-naive patients
undergoing minor and major general surgery procedures had rates of new persistent opioid use (.3
months) ranging from 5.9% to 6.5%. Similarly, in a
retrospective study of 35,817 opioid-naive patients
undergoing cardiac surgery, Brown et al21 found new
and persistent opioid use (90 to 180 days) to be 10.2 and
8.1% after undergoing coronary artery bypass grafting
and heart valve procedures, respectively. Within the
orthopaedic literature, Khazi et al22 found a rate of

April 2022, Vol 6, No 4
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MME amount when compared with all other procedures
(Table 2).

© American Academy of Orthopaedic Surgeons
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dependence could include postoperative opioid prescribing protocols, refill patterns, and physician-specific
prescribing trends. How individual surgeon characteristics, such as training background, experience, and
beliefs, contribute to opioid-prescribing patterns is a
topic that warrants further investigation.
The orthopaedic literature has consistently associated chronic opioid usage with poor outcomes. Bell
et al,9 in a large retrospective database study of 23,754
patients, found preoperative opioid usage to be an
independent risk factor in the development of periprosthetic joint infection in patients undergoing primary total joint arthroplasty (OR 1.63, P = 0.005).
Similarly, Bedard et al, in a retrospective registry study
of 17,695 patients, reported that patients who were
exposed to opioids within 3 months of primary total
hip arthroplasty had an increased risk of early revision
compared with those who were not exposed to opioids
preoperatively (1.2% versus 0.7%, P , 0.001). Furthermore, they also found that a preoperative diagnosis
of anxiety/depression had an even greater risk of early
revision (1.9% versus 0.8%, P = 0.006).8 Preoperative
and chronic opioid exposure may also signal a lower
baseline level of functioning and potential for recovery.
Kazmers et al23 assessed the effect of baseline opioid
usage on the functional and psychological outcomes in
upper extremity patients and found that patients with
chronic opioid exposure demonstrated significantly
worse scores on all patient-reported outcomes (PatientReported Outcomes Measurement Information System
[PROMIS]) and functional outcomes (PROMIS and
Quick Disabilities of the Arm, Shoulder, and Hand
[QDASH]).
Preventive measures in the form of preoperative pain
counseling have proven effective in reducing opioid usage
perioperatively.2,20 Vincent et al,2 in a prospective
randomized controlled trial of 131 patients, found that
patients undergoing upper extremity surgery who
received preoperative opioid counseling on postoperative opioid consumption consumed significantly fewer
pills than the control group who did not receive counseling (11.8 pills versus 17.4 pills, P = 0.007), with no
difference in pain scores at any time point. Similarly, a
systematic review and meta-analysis by Gazendem
et al20 concluded preoperative pain counseling effective
in overall opioid consumption.
This study is not without limitation. First, the retrospective nature of the study lends itself to the inherent
bias of retrospective study design along with the reliance
of proper documentation. However, every effort was
made to confirm accuracy of data. Second, this study
April 2022, Vol 6, No 4
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prolonged use in opioid-naive patients of 6.3% at
3 months after undergoing total shoulder arthroplasty
compared with 46% in opioid-exposed patients. Following total hip arthroplasty, Tan et al17 reported rates
of prolonged opioid use .6 months of 25.0% in opioidexposed patients compared with 2.7% of opioid-naive
patients.
Preoperative opioid use has been examined in the
orthopaedic literature. Previous studies have reported
rates of preoperative opioid exposure, ranging from
17.4% to 34.9%, and its effect on postoperative opioid
use.9,23,24 Similarly, we report a preoperative opioid
use rate of 20.8%. Preoperative opioid exposure
represents a significant risk for prolonged opioid use,
as we observed that over 60% of these patients filled
an additional opioid prescription and approximately
30% continued to fill opioid prescriptions more than
6 months postoperatively. Furthermore, over onequarter (26.4%) of opioid-naive patients filled a
second opioid prescription. We observed that preoperative opioid-exposed patients filled significantly
more prescriptions, received significantly more total
MMEs, and received significantly larger prescriptions
on average postoperatively than did preoperative
opioid-naive patients. Interestingly, preoperative
benzodiazepine use and a history of anxiety and/or
depression were only found to be risk factors for
filling a second opioid prescription, but not with
prolonged opioid use. Also, sleep apnea, often an
indication of poor overall health, was significantly
associated with prolonged opioid use, but not with
filling a second prescription.
Patient risk factors and characteristics for chronic
opioid use have also been reported in the orthopaedic
literature. Jiang et al,7 in a large database study of
79,123 patients, investigated chronic opioid use
(.3 months postoperatively) rates across different
surgical subspecialties, with the highest prevalence in
orthopaedic surgery at 23.8%, followed by neurosurgery (18.7%), and gastrointestinal surgery (14.4%).
Among potential risk factors, investigators found
underweight body mass index (OR 2.08), age 50 to 59
years (OR 2.06), and age 40 to 49 years (OR 2.01) to be
the highest risk factors for chronic use (P , 0.0001).
However, preoperative opioid status was not taken into
account. Although much of the current literature focuses
on patient-specific risk factors for developing prolonged
opioid use postoperatively, fewer studies have investigated how nonpatient factors may contribute to these
adverse outcomes. Nonpatient factors that could theoretically contribute to patients developing opioid
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only evaluated filled opioid prescriptions, which does not
always correlate with patient consumption. Third, it is
possible that patients may be obtaining additional
opioids through other avenues not recorded in the PDMP
system. Thus, it is possible that consumption is underreported in our series. Fourth, adjuvant use of multimodal nonopioid pain regimens was not evaluated.
Future investigations should examine the potential
opioid-sparing role of multimodal pain regimens.
Finally, our analysis was limited to outpatient procedures
across several subspecialties within orthopaedic surgery,
and thus, our findings may not be generalizable to all
orthopaedic procedures.
Preoperative opioid use and a history of current
smoking, sleep apnea, osteoporosis, and advanced age
were significant predictors for second opioid prescription
and prolonged use beyond 6 months after outpatient
orthopaedic surgery. It is our hope that orthopaedic
surgeons may use these characteristics to identify and
treat patients at higher risk for prolonged opioid.

